Tweets
Dr. John Cush @RheumNow ( View Tweet )
Dr. John Cush @RheumNow ( View Tweet )
The RheumNow Podcast is up – Should you Believe in Vitamin D or Rituximab? Watch it on RheumNow>> https://t.co/bX5u9KcKYz or listen to the podcast on iTunes or SoundCloud>> https://t.co/MxDcIyej3L
Links:
Dr. John Cush @RheumNow ( View Tweet )
142 pts with ANCA-Associated Vasculitis were studied for lipid levels - Lipid levels increased during remission in newly diagnosed AAV and PR3+ AAV (not MPO or relapsing pts). Lipid levels correlated w/ ESR but not other inammatory markers. https://t.co/9UgUXv6BhI
Links:
29 Patients with MDA-5+ Dermatomyositis compliated by ILD were treated with high‐dose steroids, tacrolimus, and IV cyclophosphamide +/- Plasmapheres. 6 mos survival was better (89% and 33%, respectively, P < 0.0001) compared to 15 pts not treated https://t.co/utPiaQlUZF
Links:
Dr. John Cush @RheumNow ( View Tweet )
90 SLE pts (SLEDAI<6) on immunosuppressives were given PBO or Live Virus zostavax - Vax pts had significantly higher Wk 6 anti-VZV IgG, more injection site reactions (31 vs 7%). 3 pts flared (1PBO; 2 Zostavax) and no one developed zoster postvaccination https://t.co/pVrQ4tHAwY
Dr. John Cush @RheumNow ( View Tweet )
Risk of HCQ/CQ Retinal toxicity was 5.5% in 326 SLE pts F/U x 12.8 yrs. None occured in 1st 5 yrs; earliest 8 yrs (max =33 years). Retinal toxicity cases tended to have more renal disease (22% vs 15%) and were slightly less likely to be Caucasian https://t.co/kSFVedbUPY
Dr. John Cush @RheumNow ( View Tweet )
"People don't believe what you tell them. They rarely believe what you show them. They often believe what their friends tell them. They always believe what they tell themselves." - SETH GODIN
Dr. John Cush @RheumNow ( View Tweet )
Prospective ankylosing spondylitis cohort - 628 without HTN F/U x12 mos; 200 Rx w/ NSAIDs; of these 129 developed incident HTN. NSAID use associated with incr risk of HTN (HR 1.12; CI, 1.04‐1.20), not effected by age, biologics, dz activity https://t.co/T6y5OcCgMM
Links:
Dr. John Cush @RheumNow ( View Tweet )
S.Sweden study of ANCA Assoc Vasculitis (GPA, MPA, EGPA) 195 pts followed x8 yrs: found all cancers increased (SIR=2.8). SIR for squamous cell CA=12.9; 4.3 bladder cancer, & 7.0 for pancreatic CA. CYC total <10g were not associated w/ higher CA https://t.co/wqRKaFYWGb
Dr. John Cush @RheumNow ( View Tweet )
Metanalysis of 16 studyes Systemic Sclerosis pregnancies have a higher risk of miscarriages (OR 1.6), IUGR (OR 3.2), preterm births (OR 2.4) and low birth weight (OR 3.8). SSc pts have 2.8 fold higher rate of gestational HTN & 2.3x more C- sections. https://t.co/FuM0DZFR4k
Dr. John Cush @RheumNow ( View Tweet )
Faculty Spotlight: Sherine Gabriel, MD, MSc is a rheumatologist, current president of Rush University, and Chief Academic Officer of @RushMedical will speak on the panel “How Far We Have Come” at the @WIMSummit- see her session Sept 21st! #WIMstrongertogether https://t.co/pdzXbUcHV9
Nucala (mepolizumab) was approved in 2015 for severe eosinophilic asthma, and in 2017 for EGPA (Churg Strauss). The FDA has now approved it for use in Six to 11-Year-Old Children with Severe Eosinophilic Asthma https://t.co/orAaFCkR92
Dr. John Cush @RheumNow ( View Tweet )
Novartis announced 16 wk results from the PREVENT trial - secukinumab shown to have superior ASAS40 responses in active non-radiographic axial spondyloarthritis (nr-axSpA). They estimate there are 1.7 million with nr-axSpA in the EU and US. https://t.co/IamZNN7Itc
Dr. John Cush @RheumNow ( View Tweet )
Rates of "indeterminate" results on quantiferon-IT assays were found to be significantly higher in systemic vasculitis (21%) than nonvasculitis pts and controls (7-7.5%). Indeterminate predictors were Syst vasculitis (OR 9.64), high NLR (OR 1.70). https://t.co/QqL2efsF7V
Dr. John Cush @RheumNow ( View Tweet )
